Confirmatory Study 012


Click here to start

Table of Contents

Confirmatory Study 012

PPT Slide

Eligibility Criteria

PPT Slide

Pretreatment Characteristics (I)

Pretreatment Characteristics (II)


Updated Survival

Time to Progression

Secondary Endpoint: Response Rate

Hematologic Toxicities (I)

Hematologic Toxicities (II)

Gastrointestinal Toxicities

Mucosal Toxicities

Hand-Foot Syndrome

Liver Function Tests

Concomitant Medications

Percentage of Patients with Delays or Reductions

Dose Intensity


Author: Bristol-Myers Squibb Pharmaceutical Research Institute